Background. Bloodstream infections are a major cause of morbidity and mortality worldwide, with favorable clinical outcomes associated with early optimal antibiotic selection. Rapid diagnostics have become a key part in achieving this. Biofire Filmarray® was introduced at our institution for rapid blood culture (BC) identification, coupled with antimicrobial stewardship (AS) interventions. We aimed to assess the impact of this test on time to adequate antimicrobial therapy in a setting with pre-existing effective AS interventions.
Methods. An observational retrospective chart review, pre and post study was performed. We reviewed adult positive BC before and after implementation of Biofire. Outcomes were: (1) time from BC result reported to health care provider to start of adequate antimicrobial therapy,(2) time to stopping antimicrobial therapy in BC thought to be contaminants, (3) time to any change in antimicrobial therapy and (4) a composite outcome of outcomes 1 and 2. A univariate Cox proportional hazards model was performed.
Results. 326 positive BC were analyzed, 173 before and 153 after Biofire implementation. At the time of healthcare provider notification, 77 were not on adequate antimicrobials, with median time to adequate therapy of 6.98 hours. 10.90 hours. (IQR 2.97-31.10), P = 0.87. Analysis of the composite outcome revealed a median of 
Conclusion. Implementation of the Biofire Filmarray® did not have a statistically significant effect on our composite outcome of time to adequate therapy and time to discontinuation in the case of contaminants. Our findings suggests that when added to other effective AS surveillance and interventions, the magnitude of the clinical impact of rapid PCR diagnostics for BC identification is minimal. Methods. We performed a single-center retrospective cohort study of patients who had clinical specimens sent for universal PCR from August 2013 to April 2016. Clinical data were extracted from medical records. Odds ratios were calculated and patients testing positive/negative were compared with univariate logistic regression. Sensitivity, specificity, positive predictive value and negative predictive values were calculated by comparing the test result with a gold standard composite final clinical diagnosis determined by 3 independent reviewers based on all available clinical information.
Results. 71 tissue samples were included, of which 21(29.6%) were positive. 12 bacteria, 3 mycobacteria and 7 fungi were identified. The number of leukocytes in the gram stain (odds ratio, OR 1.57, P = 0.04) and presence of inflammation on histopathological examination (OR 5.69, P = 0.02) were found to be significantly associated with a positive result. The sensitivity, specificity, positive predictive value, and negative predictive values were 56%, 95%, 91% and 70% respectively. Management was altered in 22 patients, 9 of whom had a positive and 13 had a negative result.
Conclusion. These findings suggest that the universal PCR assay has significant clinical utility, but the yield of this test can be optimized by careful patient/specimen selection. Utility was highest in patients with microscopic evidence of inflammation by gram stain or histopathlogical examination. Specificity was high. The use of this complex, difficult to interpret, and expensive test should be limited to infectious disease physicians incorporating all available clinical information to optimize performance.
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